On May 24, 2022, Dermavant Sciences Inc. published FDA’s approval for Vtama® (tapinarof) 1% cream for the topical treatment of plaque psoriasis in adult patients. Plaque psoriasis is an autoimmune disease where the patients’ immune system attacks healthy cells and is characterized by raised red patches, accompanied by itching and pain. The approval of Vtama® makes it the first drug in a new class of medications that are used to treat plaque psoriasis. This unique agent, a topical aryl hydrocarbon receptor agonist, decreases the immune system’s reaction in the skin and damage-causing oxidative agents, causing the skin condition to stabilize. The efficacy and safety of Vtama® was evaluated in two randomized, double-blind trials with a total of 1,025 participants. Vtama® showed significant treatment success compared to the placebo group that used just the vehicle cream with no active medication. In the two trials, 36% and 40% of patients who received Vtama® once daily for 12 weeks achieved complete disease clearance compared to 6% in both placebo groups. Vtama® demonstrated a favorable safety and tolerability profile. Most common adverse reactions include red raised bumps around the hair pores, pain or swelling in the nose and throat, skin rash or irritation, headache, itching, and flu. Vtama® is expected to be available from the pharmacy by prescription in early June.